Definitions

Copyright © 2025 LexisNexis

This subtopic focuses on definitions in the context of drafting for contracts. For information on boilerplate clauses in commercial business-to-business agreements, see: Boilerplate clauses—overview. For information on boilerplate in business-to-consumer contracts, see Practice Notes: Boilerplate clauses in business-to-consumer contracts—general principles and Boilerplate clauses in business-to-consumer contracts—specific clauses. For information on commercial clauses for business-to-business contracts, see: Commercial clauses—overview.

The definitions and interpretation clause of an agreement should include all of the individual defined terms that are included in an agreement and all of the provisions that are to apply to the general interpretation of an agreement and, if necessary, of certain phrases used with it. The defined terms and the interpretation provisions will normally be set out in two

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest Life Sciences News

EMA updates parallel distribution FAQ guidance

The European Medicines Agency (EMA) has updated its frequently asked questions (FAQ) guidance document on parallel distribution. The updated version includes changes to several responses concerning parallel distribution procedures, such as: (1) steps to take when an organisation’s details change; (2) what happens if a Notice for Parallel Distribution (PD) cannot be issued; (3) the obligations of parallel distributors following the issuance of a PD notice; (4) the impact of the Protocol on Ireland/Northern Ireland; and (5) clarification on who receives PD notices. In addition to these updates, EMA has added a new FAQ on the requirements for QR codes on packaging material.

Commission adopts implementing regulation on medical device clinical assessments

The European Commission has adopted an implementing regulation establishing rules for joint clinical assessments of medical devices and in vitro diagnostic medical devices under Regulation (EU) 2021/2282 (Health Technology Assessment (HTA) Regulation). The implementing regulation provides detailed procedural rules covering cooperation between the Member State Coordination Group on Health Technology Assessment and the Commission with notified bodies and expert panels, interaction protocols with health technology developers and stakeholders, general procedural rules for stakeholder consultation, and standardised formats for dossiers and assessment reports. This represents the sixth and final implementing regulation required for proper application of the HTA Regulation, which became applicable on 12 January 2025. The regulation will be published in the Official Journal from 20 October 2025, with nine joint clinical assessments currently ongoing for new cancer medicines and advanced therapy medicinal products.

Life Sciences weekly highlights—16 October 2025

This week's edition of Life Sciences weekly highlights includes analysis by Freshfields LLP of recent highlights in the UK's medical devices regulatory framework and an MLex analysis indicating that the European Commission will issue guidelines on how the EU AI Act interacts with other EU laws such as the EU GDPR. Also included is news that MedTech Europe submitted recommendations to the European Commission’s call for evidence on the forthcoming European Innovation Act, the MHRA announced an expanded partnership with the US Food and Drug Administration (FDA) to accelerate innovation in medical technologies and AI and published guidance on new medical device registration fee planned to come into effect on 1 April 2026, and the European Notified Bodies industry group (Team-NB) and the Association of British HealthTech Industries (ABHI) responded to the Commission’s call for evidence on the targeted revision of the MDR and IVDR. Also included, is news that the MHRA has awarded the first three Innovation Passports under its revised Innovative Licensing and Access Pathway (ILAP), and together with NICE have opened early access to the aligned streamlined approvals pathway six months earlier than projected, EU industry bodies have criticised the European Commission’s upcoming study on costs for implementing quaternary-level treatment upgrades under the Urban Wastewater Treatment Directive (UWWTD) and, together with Cosmetics Europe, called for a data-driven, substance-based Extended Producer Responsibility (EPR) scheme, and the European Commission opened a public consultation on its proposed European Research Area Act, among other stories.

MHRA selects seven AI healthcare technologies for AI Airlock programme Phase 2

The Medicines and Healthcare products Regulatory Agency (MHRA) has selected seven AI healthcare technologies for the second phase of its AI Airlock regulatory sandbox programme, scheduled to run until March 2026. These technologies include AI-powered clinical note taking, advanced cancer diagnostics, eye disease detection tools, and obesity treatment support systems. They address three key regulatory challenge areas: the scope of intended use extension and validation, AI-powered in-vitro diagnostic devices, and post-market surveillance with predetermined change control plans.

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

If a rentcharge is shown as being informally exonerated on title information, does this apply to the

If a rentcharge is shown as being informally exonerated on title information, does this apply to the current registered owner? Or does the informal exoneration only apply to the parties to the document which informally exonerated the rentcharge?This Q&A considers the situation where, at some

Strike out—making an application to strike out a statement of case

Strike out—making an application to strike out a statement of caseA strike out order can be made either following an application by the parties or on the court's own initiative. This Practice Note deals with the scenario of the order being made following a party's application.Making an application

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
If a rentcharge is shown as being informally exonerated on title information, does this apply to the

If a rentcharge is shown as being informally exonerated on title information, does this apply to the

If a rentcharge is shown as being informally exonerated on title information, does this apply to the current registered owner? Or does the informal exoneration only apply to the parties to the document which informally exonerated the rentcharge?This Q&A considers the situation where, at some

Strike out—making an application to strike out a statement of case

Strike out—making an application to strike out a statement of case

Strike out—making an application to strike out a statement of caseA strike out order can be made either following an application by the parties or on the court's own initiative. This Practice Note deals with the scenario of the order being made following a party's application.Making an application

Contributory negligence in personal injury claims

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an